Skip to Content
Biotechnology

The Oxford covid-19 vaccine candidate has produced promising early trial results

A nurse holds up a vaccine
A nurse holds up a vaccine
Associated Press

The news: A covid-19 vaccine candidate being developed by Oxford University and AstraZeneca proved safe and provoked a strong immune response in its first clinical trials. Participants’ systems produced both antibodies and T cells, and only relatively mild side effects were observed. The results were described today in a paper in The Lancet.

The study: The trial consisted of 1,077 healthy adults who received either the experimental vaccine, called ChAdOx1 nCoV-19, or a meningitis vaccine. Antibody responses peaked by day 28 and remained high until day 56 of the trial, which was the last day of testing. A subgroup of 10 participants who received a second dose produced even stronger antibody responses. The covid-19 vaccine also resulted in “marked increases” in T cell responses as early as day 7, and these were still present when researchers tested the participants again on the final day. T-cells are a type of white blood cell that recognize and attack an invading virus. Provoking a strong T cell response could be important: there is growing evidence it might be crucial to producing any form of lasting immunity to SARS-CoV-2.

The vaccine caused minor side effects in 70% of recipients, most commonly fatigue and headache, but these were treatable with paracetamol (acetominophen), the authors said.

Also in China: Initial results for a second vaccine candidate, being developed by CanSino Biologics in Wuhan, China, were also reported in The Lancet today. The trial of 508 healthy adults found that more than 96% of participants developed antibodies, while over 90% had T cell responses.

What’s next: While these results are promising, it’s still too early to know if either vaccine offers sufficient protection from infection—or how long any such protection might last. Further trials of the Oxford vaccine, involving more than 10,000 people, are already under way in the UK, while 30,000 people are being recruited in the US, plus 5,000 in Brazil and 2,000 in South Africa. The UK has already ordered 100 million doses of the vaccine.

Deep Dive

Biotechnology

He Jiankui
He Jiankui

The creator of the CRISPR babies has been released from a Chinese prison

He Jiankui created the first gene-edited children. The price was his career. And his freedom.

Aging Clocks concept
Aging Clocks concept

Aging clocks aim to predict how long you’ll live

These clocks promise to measure biological age and help identify anti-aging drugs, but there are lingering questions over their accuracy.

transplant surgery
transplant surgery

The gene-edited pig heart given to a dying patient was infected with a pig virus

The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

locked-in patient communicates via computer
locked-in patient communicates via computer

A locked-in man has been able to communicate in sentences by thought alone

In a world first, the man was able to ask for soup, beer, and even talk about his son for the first time since becoming completely paralyzed.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.